Bryan MacDonald

@VerveTx 3Q earnings: 1. VERVE-102 targeting PCSK9 being tested in Heart-2 trial *treated 7 patients now across 2 dose levels (0.3 mg/kg and 0.45 mg/kg) *well tolerated, no serious adverse events, no clinically significant lab abnormalities *escalation to next dose after planned DSMB *data disclosure planned in 1H 2025 2. VERVE-201 targeting ANGPTL3 - first patient has been dosed in Pulse-1 trial! 3. Continued progress on pre-clinical LPA product candidate 4. $540M in cash, runway through 2026 5. With two product candidates now in the clinic, 2025 should be an eventful year for Verve's vision 👇 ir.vervetx.com/news-releases…

Thrilled to announce that @US_FDA has cleared our *investigational new drug (IND)* application for VERVE-101 FDA reviewed our hold response which included: 1. interim clinical data from the ongoing heart-1 trial currently being conducted ex-U.S. 2. pre-clinical data to address their questions Allows us to start heart-1 trial in US to test VERVE-101 in patients living with heterozygous familial hypercholesterolemia See full release here: globenewswire.com/news-relea… $VERV @VerveTx

Idea: 2016 Company: 2018 NHP data: 2020 1st patient dosed: 2022 1st human data for in vivo liver base editing in patients with heterozygous familial hypercholesterolemia and ASCVD 👇🏽 @American_Heart @VerveTx $VERV Stay tuned!

@VerveTx approach to targets: human genetics: heterozygous & homozygous deficiency -> protection from disease, tolerated & safe human pharmacology: another Rx against target proven to work in patients These validation criteria led to prioritization of PCSK9, ANGPTL3, & LPA

UK's MHRA has awarded VERVE-101 for Rx of heterozygous familial hypercholesterolemia an Innovation Passport under Innovative Licensing & Access Pathway (intended to accelerate time to market & patient access) ir.vervetx.com/news-releases… $VERV @VerveTx

Nice graphical abstract from @escardio review on advances in dyslipidemia (L) @vervetx mission (R) Three pillars of lipoprotein risk - LDL, TRL, Lp(a) We are developing a once-&-done medicine for each: PCSK9 (LDL), ANGPTL3 (LDL & TRL), and LPA (Lp(a)) academic.oup.com/eurheartj/a…

In @CircAHA, we publish today pre-clinical data for VERVE-101 Of note, @American_Heart tells us that for Scientific Sessions '22, this abstract the highest ranked one of all submitted from U.S. #AHA22 Press release: globenewswire.com/news-relea… Paper: ahajournals.org/doi/10.1161/…

Delighted to announce a Clinical Trial Authorization (CTA) clearance by UK MHRA (Medicines and Healthcare products Regulatory Agency) for VERVE-101 as investigational Rx for patients with heterozygous familial hypercholesterolemia ir.vervetx.com/news-releases… $VERV @VerveTx

Excited to announce today: development candidate for 2nd program (VERVE-201 targeting the ANGPTL3 gene) to treat homozygous FH as well as ASCVD data to be presented by @amitvkhera @escardio 2022 Press release: ir.vervetx.com/news-releases… Data: ir.vervetx.com/static-files/… $VERV

Eventful few months @VerveTx *VERVE-101 1st patient dosed *Evolution board, addition of Lonnel Coats & Bo Cumbo *Add new target for base editing *Collaboration with Vertex *Follow-on financing *Cash runway extended to 2H 2025 $VERV ir.vervetx.com/news-releases…

2018: @VerveTx founded with concept of one-time Rx to lower LDL as low as possible for as long as possible Today: we are announcing dosing of *first patient* with VERVE-101, an in vivo CRISPR base editing medicine 🙏 to patient volunteer $VERV globenewswire.com/news-relea…

And it’s about to get real 👌🏽 ⁦@VerveTx⁩ VERVE-101 Phase 1 ClinicalTrials.gov registration now live A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease - Full Text View - ClinicalTrials.gov clinicaltrials.gov/ct2/show/…